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A model of multi-unit dose tablets of theophylline (dose, 600 mg) has been designed to give a prompt 
release dose (200 mg) in the first 1 h and the remaining sustained release dose (400 mg) to be released 
over 11 h at a first order release rate constant of 0.24 h-1. The prompt release component (A) consisted 
of conventional granules of the drug while the sustained release component (B) was made up of matrix 
granules of the drug obtained by melt granulation i.e. granulating the drug powder with a melted wax 
(carnuba). To form the multi-unit dose tablets, granules of A and B were mixed together in various 
proportions in the ratios (A: B) 2:1, 1:1 and 1:2. The disintegration times of the tablets and their 
dissolution profiles were measured to investigate consistence with the model. The results showed that 
the tablets generally disintegrated readily within 10 min irrespective of the proportion of A to B. Of the 
various formulations tested, only the formulation consisting of A and B in the ratio 1:1 gave dissolution 
profile that was comparable to that of the model. The following were the dissolution parameters of this 
formulation: the maximum release (m) = 580 mg, prompt release dose (mp) = 180 mg, time to attain 
maximum release (t) = 11 h and first order release rate constant (k1) = 0.27 h
-1 which is comparable with 
the release data for the model. The other formulations deviated by giving mp and t that were either too 
high or too low compared with those of the model. The indication is that the prompt release dose was 
not determined only by the amount of A in the multi-unit dose formulation but also by the amount of B, 
attributable to the deformation of granules of A into B during tableting. 
 





Multi-unit (MU) dosage forms consist of multiparticulate 
systems of small discrete individual units such as pellets, 
granules, microcapsules or microparticles of the same 
drug but of different release profiles. They are normally 
formulated into a single unit dosage form by filling them 
into hard gelatin capsules or compacting them into rapidly 
disintegrating tablets (Follonier and Doelker, 1992; Bod-
meier, 1997). They are expected to provide an initial 
prompt release followed by a sustained release to 
increase the duration of biologic activity of the drug. MU 
dosage forms may also consist of particles of different 
drugs to be released at different sites to prevent pharma-
cokinetic interaction.  Only the former was considered in 
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Theopylline is a methylxanthine derivative, which is 
often indicated for the treatment of asthma (Ukena et al., 
1997). It is rapidly and almost completely absorbed after 
oral administration in solution or tablet with a bioavaila-
bility of 96% (Hendeles et al., 1977). The biologic half-life 
of the drug is about 4.5 h and the usual oral dosage 
regimen is 60 to 200 mg every 3 to 4 h with a maximum 
dosage of 600 mg/day (BPC, 1980). Since asthma is a 
chronic disease requiring prolonged treatment and theo-
phylline half-life is short, several efforts have been made 
to develop sustained release dosage forms of the drug. 
Such efforts include the formation of floating lipid pellets 
of the drug to increase gastric retention and prolong 
release (Hamdani et al., 2006). The formation of matrix 
tablets using hydroxypropylmethylcellulose (HPMC) as 
binder (Moneghini et al., 2006). Reza et al. (2002) em-
ployed polyvinyl acetate and povidone as matrix former to 
form sustained release tablets of the drug. The work of 
Ochoa  et al.  (2005)  has  shown  that melt granulation of 






Figure 1. Model of dissolution profile of the multiunit dose 
tablets showing the prompt release dose (mp = 200 mg) and 
time to attain it tp (1 h), the maximum release (m = 600 mg) 




the drug (whereby the drug is triturated with a melted 
wax) is a simple process for producing matrix granules 
and tablets for sustained release applications. 
In all those efforts, there was no consideration for pro-
mpt release component, which is desirable if immediate 
relief of clinical symptoms of the ailment is to be achie-
ved. Consequently, in the present study both the prompt 
release and sustained release components have been 
considered together. A rational approach to the problem 
was adopted whereby a model of the desirable release 
profile of the MU dosage form was first developed by 
considering the drug pharmacokinetics and the published 
dosage regimen of the conventional dosage form of the 
drug. The empirical formulation of the MU dosage form 
that would meet the requirements of the model was 
experimentally determined. Moreover, the effect of such 
modeled release profile on the drug pharmacokinetic was 
considered. Preliminary studies showed drug release 
from the matrix granules were more retarded when the 
granules were tableted rather than filled into hard gelatin 
capsules. Hence, the present study focuses on the multi-





Modeling of the desirable drug release profile for the 
multi-unit dose tablet 
 
The model (Figure 1) was developed based on the 
following considerations: 
 





daily to a maximum daily dose of 600 mg (BPC, 1980). 
This means that the total daily dose in the MU dosage 
form should be 600 mg divided into a prompt release 
dose (200 mg) and the sustaining dose, 400 mg.  
(ii) From the drug pharmacokinetics, the tmax (time for 
peak absorption or to attain peak plasma level) is 2 h 
(BPC, 1980), therefore the prompt dose should be 
released at least 1 h giving another 1 h to attain the peak 
plasma concentration.  
(iii) The sustained release dose (400 mg) will be released 
over 11 h at an average rate of 36 mgh-1 such that the 
time for maximum release will be 12 h for the dose to be 
taken once 12 hourly.  
(iv) Drug release from the system is based on first order 
rate kinetics, which is the most frequently reported rate 
order kinetic in the literature for the dissolution of drug 
particles and their solid dosage forms (Richards, 1972; 
Eichie and Okor, 2002). Preliminary investigation in the 
present study also confirmed the literature report.  
(v) The first order rate kinetics is given by the equation 
(Richards, 1972):  
 
log mt = log m0 – 0.43k1t ………………………… (1)                                                      
 
where m0 is the initial amount of drug (400 mg) at the 
beginning of the sustained release, mt is the residual 
amount (36 mg) of drug in time, t, 10 h (i.e. 1 h before 
maxi-mal release), k1 is the first order release rate 
constant. Hence, substituting these values in equation 1, 
gives:  
 
log 36 = log 400 – 0.43 k110 
 
1.556 = 2.602 – 0.43 k110 
 
1.556 - 2.602 = - 4.3 k1  
 
-1.046 = -4.3 k1 
 
From where,  
 
k1 = 1.046/4.3 = 0.24 h
-1 indicating that the sustained 
release will proceed at a first order rate, 0.24 h-1. 
 
With known values of m0 and k1, the amounts of drug 
release at predetermined time intervals were estimated 
from equation 1, and the data were plotted to give the 
theoretical release curve (Figure 1). The main features of 
the release profile of the model are the prompt release 
dose (mp = 200 mg), maximum release (m = 600 mg) 
and the time to attain it (t = 12 h). Thus, the ideal MU 
dosage form should display this drug release profile. An 
example of the calculation of amount released after a 
given time interval is as follows: 
Given that the time for prompt release tp = 1 h and mp = 
200 mg, at 5 h sampling time, the interval between 5 h 
and tp will be (t - tp) = 5 – 1 = 4 h. Hence, the value of mt 







Figure 2. Model of the plasma level profile of the conventional 
dosage form based on the drug (theophylline) pharmacokinetics. 
Cmax = 6.4 mg/ml, ka = 0.023 min
-1
, ke = 0.00257 min
-1, minimum 
therapeutic level = 5 mg/ml and minimum toxic level = 9 mg/ml. 




log mt = log 400 – 0.43 × 0.24 × 4 
 
log mt = 2.602 – 0.4128 
 
log mt = 2.1892, and mt = 155 mg 
 
Therefore, the residual amount is 155 mg and the 
amount released will be 400 – 155 = 245 mg in the 4 h 
interval after tp. The cumulative release including the mp 
will be (245 + 200) mg = 445 mg. 
The expected effect of this modified release profile 
(Figure 1) on the duration of bioactivity of the drug was 
obtained by modeling the absorption/elimination curves 
for the conventional as well as the MU dose tablets. 
 
 
Theoretical estimation of the duration of bioactivity 
following a single dose (200 mg) of the conventional 
tablets form  
 
This was achieved by modeling the absorption/elimina-
tion curve for the conventional tablets. The model for the 
absorption curve (Figure 2) was developed based on the 
following considerations:  
 
(i) From the literature (Hendeles et al., 1977), the 
percentage bioavalability of theophylline tablets is 96%; 
therefore the amount that will be bioavailable at tmax 
following a prompt release dose (200 mg) will be 0.96 x 
200 mg = 192 mg. 
(ii) The relationship between the peak plasma concen-
tration (Cp), the apparent volume of distribution (Vd) and 
the bioavailable dose (D) is given by (Raymond and 
Graig, 2000): 




D = CpVd ……………………………….………. (2)  
 
For theophylline, Vd = 30,000 ml (BPC, 1980) and D = 
192 mg, which gives Cp = D/Vd = 192 mg/30000 ml = 
0.0064 mg/ml or 6.4 µg/ml as the peak plasma level at 
tmax (2 h).  
(iii) The peak plasma concentration 6.4 µg/ml will be 
attained in 2 h at an average rate of 0.053µg/ml/min 
being the quotient of 6.4µg/ml/120min. (iv) The absorp-
tion curve is based on the first order rate kinetics 
(Richards, 1972), thus: 
 
log Cp = log Co + 0.43kat …………… ………… (3) 
 
where Cp is the plasma concentration in time t, Co is 
plasma concentration in the first sampling time (say at 10 
min) and ka is the absorption rate constant. Thus, at t = 
10 min, Co = 0.53 µg/ml being the product of 10 × 0.053 
µg/ml. At peak plasma concentration, Cp= Cmax = 6.4 
µg/ml and t = tmax-10 that is (120 - 10) = 110 min. 
 
Substituting in equation 3, the values of Cp, C0 and t 
gives 
 
log 6.4 = log 0.53 + 0.43ka 110 
 
0.8062 = -0.2757 + 47.3 ka 
 
0.8062 + 0.2757 = 47.3 ka 
 
From where:  
 
ka = 1.085/47.3 = 0.023 min-1. 
 
Substituting the ka and Co values into equation 3 gave the 
plasma concentrations at the various time intervals up to 
the tmax, (2 h) as given in Figure 2.  
The elimination curve was based on the first order 
elimination kinetics: 
 
log Cp = log Cmax – 0.43ket ……………… ……. (4)   
 
where ke is elimination rate constant = 0.693/t1/2 and t1/2 
for theophylline = 4.5 h (BPC 1980), hence ke = 0.00257 
min-1. Cp is the plasma concentration at time, t and Cmax 
is the peak plasma concentration before elimination beg-
ins. Substituting into equation 4, the values of Cmax = 6.4 
µg/ml and ke = 0.00257 min-1 gave the values of Cp at 
the various time intervals in the elimination phase. For 
instance, at 20 min into the elimination phase, log Cp = 
log 6.4 – 0.43 × 0.00257 × 20 = 6.1 µg /ml. The duration 
of bioactivity was estimated by considering the minimum 
therapeutic plasma level, which is 5 µg/ml (BPC 1980). 






Figure 3. Model of the plasma level profile of the multiunit dosage 
form based on the drug pharmacokinetics and published dosage 




Estimation of the duration of bioactivity following a 
single dose of the multi-unit dose tablets  
 
This was achieved by modeling the absorption/elimina-
tion curve for the MU dose tablets. The model (Figure 3) 
was developed based on the following considerations: 
 
(i) The peak plasma concentration due to the prompt 
release fraction is 6.4 µg/ml, tmax = 2 h, the minimum 
therapeutic level is 5 µg/ml while the minimum toxic level 
is 9 µg/ml (BPC, 1980).  
(ii) There would be a plateau between the tmax (2 h) to 13 
h assuming that drug release and absorption are 
sustained for the next 11 h after attaining peak plasma 
concentration in 2 h. The plateau in the plasma level 
profile will arise if the absorption and elimination rates are 
equal. The absorption rate was estimated to be 1.17 
µg/ml/h as follows: 
As given previously (Figure 1), the sustained release 
dose (400 mg) should be released in 11 h (i.e. average 
release rate is 36 mgh-1). Since the oral bioavailability is 
96%, the absorption rate will be 0.96 × 36 mg/h = 35 
mgh-1. The corresponding rate of increase in plasma con-
centration is given as 35 mg h-1/Vd = 1.17 µg/ml/h, given 
that Vd = 30,000 ml. Hence, the absorption rate in the 
sustained release phase is = 1.17 µg/ml/h. On the other 
hand, the average elimination rate in the sustained relea-
se phase was estimated to be 0.80 µg/ml/h on the basis 
that t1/2 is the time for peak plasma concentration (6.4 
µg/ml) to fall to 50% of its original value. Given that t1/2 for 
theophylline = 4.5 h (BPC, 1988), the average rate of 
drug elimination will be [(6.4/2) µgml-1 /4.5 h] ≈ 0.8 
µg/ml/h. Both the average absorption and the elimination 
rates can be approximated to unity. Hence, in the model-
ing the absorption and elimination rates were assumed to 
be equal, thus giving rise to the plateau in Figure 3. This 





sustained for 11 h before elimination commences at 
same rate as for the conventional tablets (Figure 2). The 
duration of bioactivity of the MU tablets was estimated by 
considering that the therapeutic plasma level of the drug 
is 5 µg/ml as indicated in Figure 3. 
 
 




Carnuba wax (Halewood Chemicals Limited, England) is a fine 
waxy solid with melting point of 82 - 88C, yellowish in colour and 
was used as the granulating agent and the matrix former. Maize 
starch (BDH, Chemical, Poole, UK) was used as binder in the form 
of mucilage (20%, w/v) to produce the conventional granules. The 
maize starch (5%, w/w) was also used as disintegrant, as dried 
powder. Magnesium stearate (Sakai Chemical Company, Japan) 
was used as lubricant at a concentration of 0.5%, w/w in the tablet 
formulations. The test drug was theophylline (Sigma Chemical 




Wet granulation to form the conventional granules 
 
A sample of the theophylline powder (100 g) was wet-massed with 
starch mucilage (20%, w/v). Hence, the content of starch binder in 
the resulting granules was 16.7%, w/w. The wet mass was pressed 
through a sieve of aperture size 1.7 mm, spread thinly on trays and 
then dried at 50C for 1 h in a hot air oven (Kottermann, Germany). 
The half dried mass was pressed through a sieve of aperture size 
710 µm and dried finally at 50C for 2 h to moisture content of 2.1 ± 
0.3%, w/w. These granules are designated here as A. 
 
 
Melt granulation to form the matrix granules  
 
The wax material (20 g) was melted in a stainless steel container in 
a water bath at a temperature higher than the melting point of the 
wax (i.e. 90C). A sample of the theophylline powder (100 g) was 
then added to the melted wax and mixed well with a glass rod, then 
allowed to cool to room temperature (30C). The mass was pressed 
through a sieve of mesh 10 (aperture size; 710 µm) to produce mat-
rix granules that will not disintegrate in aqueous fluid to their pri-
mary (powder) particles. These granules are designated here as B. 
 
 
Preparation of the multi-unit dose tablets 
 
The conventional (A) as well as the matrix granules (B) were mixed 
together in different proportions in the ratios 2:1, 1:1, 1:2, (A: B). In 
each mixture, aliquots of the granules were selected such that the 
total drug content in a tablet was 300 mg; representing the contri-





The conventional, (A) and the matrix (B) granules, or their admix-
tures (A and B) were compressed using a single punch tableting 
machine (Manesty Type F3, Poole, England) at a constant load (30 
arbitrary units on the load scale) to form flat faced tablets of 
diameter 12.5 mm. The weights of the tablets varied depending on 
the formulation but the drug content in each tablet remained 300 
mg. Magnesium stearate (0.5%, w/w) and dried maize starch pow-
der (5%, w/w) were added to the granules prior to compression. 








Figure 4. Release profiles of A () or B () alone, initial drug con-




Determination of tablet tensile strength (T) and disintegration 
times (DT) 
   
T is the stress needed to fracture a tablet by diametral compres-
sion. It is given by the expression (Fell and Newton, 1970): 
 
T= 2P/π………………………………………. (5) 
 
where P is the fracture load that causes tensile failure of a tablet of 
diameter, D and thickness, t. The fracture loads (Kg) of ten tablets 
were determined individually with the Monsanto hardness tester, 
following Brook and Marshal (1968). The mean values of the frac-
ture loads were used to calculate the T values for the various tab-
lets. To measure DT values, the method described in the British 
Pharmacopoeia (2002) was followed using water maintained at 37 ± 
2C as the disintegration fluid. Six tablets were used in each deter-






The stirred beaker method described previously by Okor et al. 
(1991) was followed. Two tablets were placed in a cylindrical basket 
(aperture size 425 µm, diameter 20 mm; height 30 mm), which was 
immersed in 800 ml of leaching fluid (0.1 N hydrochloric acid main-
tained at 37 ± 2oC). The fluid was stirred at 100 rpm with a single 
blade GallenKamp stirrer (Model APP No 4B 5784A). Samples of 
the leaching fluid (5 ml) were withdrawn at selected time intervals 
with a pipette fitted with a cotton wool plug and replacing with an 
equal volume of drug-free dissolution fluid. The samples were suita-
bly diluted with blank dissolution fluid and were analysed for content 
of theophylline spectrophotometrically at λ max, 272 nm (Model 
Spectronic 21D, Bausch and Lomb, USA). The samples were filte-
red before assay. The dissolution test was carried out in quadrupli-
cate and the mean results reported. Individual results were repro-
ducible to ± 10% of the mean. The release data were subjected to 
student t test (p > 0.05) to test for significance of difference bet-
ween paired data. 




RESULTS AND DISCUSSION 
 
Tablet disintegration times and tensile strength 
 
The disintegration times (DT) of the multi-unit dose tab-
lets are 6, 8 and 9 min for multi-unit dose tablets in the 
ratios (A: B) 2:1, 1:1 and 1:2 respectively. This showed 
that all the multiunit dose tablets disintegrated readily 
during disintegration test. The tablet tensile strengths (T) 
for the multi-unit dose tablets were (MNm-2) 1.56, 1.62 
and 1.67. Thus, tablets with higher proportion of granules 
B (i.e. the matrix granules) tended to give slightly longer 
disintegration times and slightly higher tensile strengths, 
but the differences were not statistically significant (p > 
0.05). The DT and T values of tablets of B were however 
significantly higher than those of A which indicated that 
carnuba wax (the matrix former) promoted particle defor-
mation and bonding during tableting as previously repor-
ted (Uhumwangho and Okor, 2006).  
 
 
Release profiles of tablets of the components A or B 
 
The release curves for A and B measured separately are 
given in Figure 4.The features of the release profile for A 
include a high prompt release dose (348 mg) and a slow 
t∞ (5 h) while that of B include a low prompt release (156 
mg) and a prolonged t∞ (12 h). Thus A alone suffers the 
deficiency of a sustained release while B suffers the defi-
ciency of inadequate prompt release needed for imme-
diate relief of clinical symptoms. Hence, the need to inclu-
de A and B in a unit dose. 
 
 
Release profiles of the multi-unit (MU) dose tablets  
 
The release profiles of the multi-unit dose tablets are pre-
sented in Figure 5. The dotted line in the graph repre-
sents the release profile for the model. The actual (empi-
rically determined) release curves for the MU dose tab-
lets of compositions of A and B are presented as full lines 
in the graph for comparison with the model. The release 
parameters deduced from these curves are presented in 
Table 1. From where it can be seen that the multi-unit 
tablets of composition 1:1 (A: B) gave a comparable rele-
ase profile as that of the MU model (Figure 1). The 
values of the release parameters for the multi-unit tablets 
of composition 1:1 (A: B) being, mp (180 mg), t (11 h) 
and k1 (0.27 h
-1) against the corresponding values for the 
model mp (200 mg), t (12 h) and k1 (0.24 h
-1). By incor-
porating a prompt release fraction (A) up to 300 mg in the 
multi-unit tablets, it was possible to achieve a prompt 
release dose of nearly 200 mg in the first 1 h. With A 
alone in the tablet, virtually all the 300 mg drug content 
was released in the first 1 h. This means that the presen-
ce of B in the multi-unit dose for tablets lowered the 
extent of prompt lease from A. Also, it was expected that 
the MU formulation of composition A (200 mg) and B 
(400mg) would provide the targeted prompt release dose  






Figure 5. Cumulative release of theophylline from the MU 
tablets of the conventional (A) and matrix granules (B) 
mixed in different ratios (A:B), 1:2 (), 1:1 (), 2:1 (), (∆). 





Table 1. A comparison of the empirical release data m, mp, t 
and k1 values for MU tablets of A and B mixed in different 
proportions. 
 
A:B ratios Parameters 
evaluated 1:2 1:1 2:1 Model 
m (mg) 578 580* 584 582* 
mp (mg) 128 180* 240 200* 
t (h) 12 11* 9 12* 
k1 (h-1) 0.28 0.27* 0.41 0.24* 
 




of 200 mg (Figure 1), which was not the case. The actual 
prompt release was 128 mg; considerably less than the 
targeted 200 mg. This observation relates to the deforma-
tion of A and B particles into each other during tableting 
such that the tablets did not disintegrate to particles of A 
and B separately. Ideally, MU tablets should disintegrate 
yielding the component particles intact so as to retain the 




Consideration of the effect of the modified release 
profile on the duration of drug activity 
 
It was not possible at this stage of this work to determine 
clinically the duration of bioactivity of the modified (MU) 





roval for clinical trials on new products. However, by 
modeling the absorption/elimination curves of the con-
ventional and the modified dosage forms it was estimated 
that the duration of bioactivity following a single dose of 
the conventional dosage form would be about 2 h (Figure 
2) as against 12 h for the modified (MU) dosage form 
(Figure 3). This means that the modified dosage form can 





The study has shown that multi-unit dose tablets consis-
ting of A and B in the ratio 1:1 will give a prompt release 
followed by a prolonged and sustained release as design-
ned in the model. Since particles of A and B are defor-
med into each other during tableting, it would be erro-
neous to assume that the amount of A in the multi-unit 
dose tablets would automatically represent the prompt 
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